TMCnet News
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare ConferenceSAN DIEGO --(Business Wire)-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 9th Annual JMP Securities (News - Alert) Healthcare Conference taking place June 24-25 in New York City. The 9th Annual JMP Securities Healthcare Conference Presentation Details
About La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS (News - Alert)-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. GCS-100 currently is in Phase 2 clinical development for chronic kidney disease (CKD). LJPC-501, the Company's second product candidate, is a natural peptide for the potential treatment of hepatorenal syndrome. LJPC-401, the Company's third product candidate, is a natural peptide for the potential treatment of iron overload. For more information on the Company, please visit http://www.ljpc.com.
|
